An update on treatment of onychomycosis

Mycoses

Volumn 55, Issue 6, 2012, Pages 541-551

  Grover, Chander ^a   Khurana, Ananta ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Antifungal agents; Keratinophilic fungi; Tinea unguium

Indexed keywords

ALPHA TOCOPHEROL; AMOROLFINE; BIFONAZOLE; BUTENAFINE; CICLOPIROX; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; POSACONAZOLE; RAVUCONAZOLE; SOUR ORANGE EXTRACT; TERBINAFINE; TIOCONAZOLE; TOLNAFTATE; VORICONAZOLE;

ABDOMINAL PAIN; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; AGRANULOCYTOSIS; ANTIFUNGAL RESISTANCE; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTACT DERMATITIS; DEBRIDEMENT; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHEMA MULTIFORME; FEMTOSECOND LASER; FINGERNAIL ONYCHOMYCOSIS; FLATULENCE; FUNGICIDAL ACTIVITY; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; IONTOPHORESIS; LIVER INJURY; LOW LEVEL LASER THERAPY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NEODYMIUM YAG LASER; NON DERMATOPHYTE ONYCHOMYCOSIS; NONHUMAN; ONYCHOLYSIS; ONYCHOMYCOSIS; PANCYTOPENIA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN PRURITUS; STEVENS JOHNSON SYNDROME; SYSTEMIC THERAPY; TASTE DISORDER; TOENAIL ONYCHOMYCOSIS; TOPICAL TREATMENT; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; ULTRASOUND; ULTRAVIOLET C RADIATION;

ANIMALS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; HUMANS; ONYCHOMYCOSIS;

FUNGI;

EID: 84867567487     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2012.02199.x     Document Type: Review

References (96)

1. Szepietowski JC, Reich A. Stigmatisation in onychomycosis patients: a population-based study. Mycoses 2009; 52: 343-9.
2. Kozarev J, Vižintin Z. Novel laser therapy in treatment of onychomycosis. J LAHA 2010; 1: 1-8.
3. Schlefman BS. Onychomycosis: a compendium of facts and a clinical experience. J Foot Ankle Surg 1999; 38: 290-302.
4. Haneke E, Roseeuw D. The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 1999; 38: 7-12.
5. Ghannoum MA, Hajjeh RA, Scher R et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641-8.
6. Warshaw EM, Foster JK, Cham PM, Grill JP, Chen SC. NailQoL: a quality-of-life instrument for onychomycosis. Int J Dermatol 2007; 46: 1279-86.
7. Szepietowski JC, Reich A, Pacan P, Garlowska E, Baran E. Evaluation of quality of life in patients with toenail onychomycosis by Polish version of an international onychomycosis-specific questionnaire. J Eur Acad Dermatol 2007; 21: 491-8.
8. Roujeau JC, Sigurgeirsson B, Korting HC, Kerl H, Paul C. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulites of the leg: a case-control study. Dermatology 2004; 209: 301-7.
9. Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R. Treatment options - development of consensus guidelines. J Eur Acad Dermatol Venereol 2005; 19(Suppl. 1): 25-33.
10. Baran R, De Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol 1996; 76: 82-3.
11. Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003; 149(Suppl. 65): 5-9.
12. Scher RK, Tavakkol A, Sigurgeirsson B et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007; 56: 939-44.
13. Roberts DT, Evans EG. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998; 138: 189-90.
14. Burkhart CN, Burkhart CG, Gupta AK. Dermatophytoma: recalcitrance to treatment because of existence of fungal biofilm. J Am Acad Dermatol 2002; 47: 629-31.
15. Faergemann J, Correia O, Nowicki R, Ro BI. Genetic predisposition - understanding underlying mechanisms of onychomycosis. J Eur Acad Dermatol Venereol 2005; 19: 17-9.
16. Gupta AK, Uro M, Cooper EA. Onychomycosis therapy: past, present, future. J Drugs Dermatol 2010; 9: 1109-13.
17. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: A 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353-7.
18. Iorizzo M, Piraccini BM, Tosti A. Today's treatment options for onychomycosis. J Dtsch Dermatol Ges 2010; 8: 875-9.
19. Repka MA, O'Haver J, See CH, Gutta K, Munjal M. Nail morphology studies as assessments for onychomycosis treatment modalities. Int J Pharm 2002; 245: 25-36 1.
20. Abadi D, Zderic V. Ultrasound-mediated nail drug delivery system. J Ultrasound Med 2011; 30: 1723-30.
21. Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007; 20: 31-46.
22. Baran R, Hay RJ, Garduno JI. Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J Dermatol Treat 2008; 19: 72-81.
23. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43: S57-69.
24. Ulbricht H, Worz K. Therapy of onychomycosis due to moulds with ciclopirox nail lacquer. Mycoses 1994; 37: 97-100.
25. Gupta AK, Ryder JE, Baran R. The use of topical therapies to treat onychomycosis. Dermatol Clin 2003; 21: 481-9.
26. Polak A. Preclinical data and mode of action of amorolfine. Dermatology 1992; 184(Suppl. 1): 3-7.
27. Rigopoulos D, Katsambas A, Antoniou C, Christofidou E, Balaskas E, Stratigos J. Discoloration of the nail plate due to the misuse of amorolfine 5% nail lacquer. Acta Derm Venereol 1996; 76: 83-4.
28. Kim BJ, Ro BI. Hyperpigmentation due to the overuse of amorolfine nail lacquer. Korean J Med Mycol 2002; 7: 224-6.
29. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 17(Suppl. 1): 41-3.
30. Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology 1992; 184(Suppl. 1): 21-4.
31. Hardjoko FS, Widyanto S, Singgih I, Susilo J. Treatment of onychomycosis with a bifonazole-urea combination. Mycoses 1990; 33: 167-71.
32. Schaller M, Borelli C, Berger U et al. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. Med Mycol 2009; 47: 753-8.
33. Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution - an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111-5.
34. Ghannoum MA, Long L, Pfister WR. Determination of the efficacy of terbinafine hydrochloride nails solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 2009; 52: 35-43.
35. Nair AB, Vaka SR, Sammeta SM et al. Trans-ungual iontophoretic delivery of terbinafine. J Pharm Sci 2009; 98: 1788-96.
36. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007; 18: CD001434.
37. Haugh M, Helou S, Boissel JP, Cribier BJ. Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol 2002; 147: 118-21.
38. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126: 2-7.
39. Darkes MJ, Scott LJ, Goa KL. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol 2003; 4: 39-65.
40. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150: 537-44.
41. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a post-marketing surveillance study in 25.884 patients. Arch Dermatol 1997; 133: 1213-9.
42. Stricker BH, van Riemsdijk MM, Sturkenboom MC, Ottervanger JP. Taste loss to terbinafine: a case-control study of potential risk factors. Br J Clin Pharmacol 1996; 42: 313-8.
43. Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH. A cohort study of the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999; 48: 847-52.
44. Rzany B, Mockenhaupt M, Gehring W, Schöpf E. Stevens-Johnson syndrome after terbinafine therapy. J Am Acad Dermatol 1994; 30: 509.
45. Carstens J, Wendelboe P, Sogaard H, Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Dermatol Venereol 1994; 74: 391-2.
46. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 1996; 23: 259-62.
47. Tosti A, Piraccini BM, Stinchi C, Venturo N, Bardazzi F, Colombo MD. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595-600.
48. Warshaw EM, Carver SM, Zielke GR, Ahmed DD. Intermittent terbinafine for toenail onychomycosis: is it effective? Results of a randomized pilot trial. Arch Dermatol 2001; 137: 1253.
49. Pavlotsky F, Armoni G, Shemer A, Trau H. Pulsed versus continuous terbinafine dosing in the treatment of dermatophyte onychomycosis. J Dermatolog Treat 2004; 15: 315-20.
50. Gupta AK, Lynch LE, Kogan N, Cooper EA. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol 2009; 23: 256-62.
51. Segal R, Kritzman A, Cividalli L, Samra Z, David M, Tiqva P. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35: 958-61.
52. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994; 130(Suppl. 43): 16-21.
53. Cribier BJ, Bakshi R. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations in patients with nondermatophyte infections. Br J Dermatol 2004; 150: 414-20.
54. Scher RK, Breneman D, Rich P et al. Once weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38(6 pt 2): S77-86.
55. Ling MR, Swinyer IJ, Jarratt MJ et al. Once weekly fluconazole (450mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38(6 Pt 2): S95-102.
56. Havu V, Heikkilä H, Kuokkanen K et al. A double blind randomized sudy to compare the efficacy and safety of terbinafine (Lamisil) and fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol 2000; 142: 97-102.
57. Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology 2001; 202: 235-8.
58. Gupta A, Leonardi C, Stoltz RR, Pierce PF, Conetta B. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005; 19: 437-43.
59. Dunand J, Viguie C, Paugam A. Intermittent posaconazole regimen to treat superficial Scytalidium dimidiatum infection. Eur J Dermatol 2010; 20: 649-50.
60. Sarifakioglu E, Seçkin D, Demirbilek M, Can F. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium. Clin Exp Dermatol 2007; 32: 675-9.
61. Scheinfeld N. A review of the new antifungals: posaconazole, micafungin, and anidulafungin. J Drugs Dermatol 2007; 6: 1249-51.
62. Hochman LG. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. J Cosmet Laser Ther 2011; 13: 2-5.
63. Manevitch Z, Lev D, Hochberg M, Palhan M, Lewis A, Enk CD. Direct antifungal effect of femtosecond laser on Trichophyton rubrum onychomycosis. Photochem Photobiol 2010; 86: 476-9.
64. Bornstein E. A review of current research in light-based technologies for treatment of podiatric infectious disease states. J Am Podiatr Med Assoc 2009; 99: 348-52.
65. Dai T, Tegos GP, Rolz-Cruz G, Cumbie WE, Hamblin MR. UVC inactivation of dermatophytes. Br J Dermatol 2008; 158: 1239-46.
66. Qiao J, Li R, Ding Y, Fang H. Photodynamic therapy in the treatment of superficial mycoses: an evidence-based evaluation. Mycopathologia 2010; 170: 339-43.
67. Harris F, Pierpoint L. Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev doi: 10.1002/med.20251 [Epub ahead of print].
68. Donnelly RF, McCarron PA, Lightowler JM, Woolfson AD. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J Control Release 2005; 103: 381-92.
69. Baran R, Tosti A. Chemical avulsion with urea nail lacquer. J Dermatolog Treat 2002; 13: 161-4.
70. Bonifaz A, Ibarra G. Onychomycosis in children: treatment with bifonazole-urea. Pediatr Dermatol 2000; 17: 310-4.
71. Dorn M, Kienitz T, Ryckmanns F. Onychomycosis: experiences with atraumatic nail avulsion. Hautarzt 1980; 31: 30-4.
72. Malay DS, Yi S, Borowsky P, Downey MS, Mlodzienski AJ. Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial. J Foot Ankle Surg 2009; 48: 294-308.
73. Jennings MB, Pollak R, Harkless LB, Kianifard F, Tavakkol A. Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial. J Am Podiatr Med Assoc 2006; 96: 465-73.
74. McInnes BD, Dockery GL. Surgical treatment of mycotic toenails. J Am Podiatr Med Assoc 1997; 87: 557-64.
75. Potter LP, Mathias SD, Raut M, Kianifard F, Landsman A, Tavakkol A. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat 2007; 18: 46-52.
76. Harman S, Ashbee HR, Evans EG. Testing of antifungal combinations against yeasts and dermatophytes. J Dermatolog Treat 2004; 15: 104-7.
77. Polak A. The past, present and future of antimycotic combination therapy. Mycoses 1999; 42: 355-70.
78. Baran R, Feuilhade M, Combemale P et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 2000; 142: 1177-83.
79. Lecha M, Alsina M, Torres Rodriguez JM et al. An open-label, multicenter study of the combination of amorolfine nails lacquer and oral itraconazole compared with oral itraconazole alone in the treatment of severe toenail onychomycosis. Curr Ther Res 2002; 63: 366-79.
80. Grover C, Bansal S, Nanda S, Reddy BS, Kumar V. Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial. Br J Dermatol 2007; 157: 364-8.
81. Bonifaz A, Guzmán A, Garcia C, Sosa J, Saúl A. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Int J Dermatol 1995; 34: 500-3.
82. Roberts DT, Hay RJ, Doherty VR, Richardson MD, Clayton YM. Topical treatment of onychomycosis using bifonazole 1% urea/40% paste. Ann NY Acad Sci 1988; 544: 586-7.
83. Pierard GE, Pierard-Franchimont C, Arrese JE. The boosted antifungal topical treatment (BATT) for onychomycosis. Med Mycol 2000; 38: 391-2.
84. Pierard GE, Pierard-Franchimont C, Arrese JE. The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology 2000; 200: 185-7.
85. Gupta AK, Drummond-Main C, Cooper EA, Brintnell W, Piraccini BM, Tosti A. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol 2011; 66: 494-502.
86. Tosti A, Piraccini BM, Lorenzi S, Iorizzo M. Treatment of nondermatophyte mold and Candida onychomycosis. Dermatol Clin 2003; 21: 491-7.
87. Gupta AK, Kohli Y. Evaluation of in vitro resistance in patients with onychomycosis who fail antifungal therapy. Dermatology 2003; 207: 375-80.
88. da Silva Barros ME, de Assis Santos D, Hamdan JS. Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method. J Med Microbiol 2007; 56(Pt 4): 514-8.
89. de Assis Santos D, de Carvalho Araújo RA, Kohler LM, Machado-Pinto J, Hamdan JS, Cisalpino PS. Molecular typing and antifungal susceptibility of Trichophyton rubrum isolates from patients with onychomycosis pre- and post-treatment. Int J Antimicrob Agents 2007; 29: 563-9.
90. Santos DA, Hamdan JS. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med Mycol 2006; 44: 357-62.
91. Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother 2003; 47: 82-6.
92. Méndez-Tovar LJ, Manzano-Gayosso P, Velásquez-Hernández V et al. Resistance to azolic compounds in clinical Trichophyton spp. strains. Rev Iberoam Micol 2007; 24: 320-2 31.
93. Sigurgeirsson B, Olafsson JH, Steinsson JT, Kerrouche N, Sidou F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol 2010; 24: 910-5.
94. Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 2010; 62: 411-4.
95. Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 1998; 197: 162-6.
96. Yin Z, Xu J, Luo D. A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole. J Dermatolog Treat 2011; [Epub ahead of print].